药丸用于癌症治疗的前景。
The prospect of pill in the treatment of cancers.
作者信息
Chen Zehui, Li Zhiming, Yang Shuo, Wei Yue, An Jing
机构信息
Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, 100029, China.
出版信息
Heliyon. 2023 Apr 14;9(4):e15490. doi: 10.1016/j.heliyon.2023.e15490. eCollection 2023 Apr.
BACKGROUND
pill, a Traditional Chinese Medicine (TCM) prescription and a representative of therapy (one of the TCM therapies to promote blood circulation and remove blood stasis), has been widely used in breast cancer treatments. Although some evidence suggests the efficacy and safety of the pill in treating certain cancer, the overall efficacy of the pill in other cancer treatment is uncertain.
OBJECTIVE
This study aimed to summarize the current clinical literature and provided evidence support for addressing the research question of whether the pill is safe and effective in the treatment of various cancers as therapy, and possibly identify the clinical dosage range and therapeutic effect of pills.
METHOD
Seven Chinese and English databases such as PubMed, CNKI, and Google Scholar were searched to collect the publications on pill and cancer. Then the researchers extracted data from the articles that met the inclusion criteria and used SAS statistical program version 9.4 (by SAS Institute, Cary, North Carolina, USA) for statistical statistics.
RESULTS
Our search identified 78 studies, including 69 RCTs (randomized control trials), 6 NRCCs (non-randomized concurrent control trials), and 3 BAS (before-after study), evaluating 3151 patients in total. The daily doses of pills/capsule were between 2 g and 60 g, and duration between 2 weeks and 5 years, mostly used in the middle or late stage of cancer. The therapeutic effect of the pill was mainly reflected in improving Complete Response (CR, a term from The Response Evaluation Criteria In Solid Tumors) or Partial Response (PR, a term from The Response Evaluation Criteria In Solid Tumors), reducing adverse reactions, promoting quality of life (QoL), regulating immunity, alleviating pain, prolonging survival, reducing metastasis and recurrence, reducing inflammation, regulating estrogen levels, decreasing hypercoagulative status, and reducing tumor markers.
CONCLUSION
pill representing therapy has a good prospect in the treatment of cancer.
背景
某中药方剂是一种传统中药处方，也是化瘀疗法（促进血液循环、消除血瘀的中医疗法之一）的代表方剂，已广泛应用于乳腺癌治疗。尽管有证据表明该方剂在治疗某些癌症方面的有效性和安全性，但该方剂在其他癌症治疗中的总体疗效尚不确定。
目的
本研究旨在总结当前临床文献，为解决该方剂作为化瘀疗法治疗各种癌症是否安全有效的研究问题提供证据支持，并可能确定该方剂的临床剂量范围和治疗效果。
方法
检索了PubMed、中国知网、谷歌学术等7个中英文数据库，以收集关于该方剂与癌症的出版物。然后，研究人员从符合纳入标准的文章中提取数据，并使用美国北卡罗来纳州卡里市SAS研究所的SAS统计软件9.4版进行统计分析。
结果
我们的检索共识别出78项研究，包括69项随机对照试验、6项非随机同期对照试验和3项前后对照研究，共评估了3151例患者。该方剂/胶囊的日剂量在2克至60克之间，疗程在2周至5年之间，主要用于癌症中晚期。该方剂的治疗效果主要体现在提高完全缓解率（CR，实体瘤疗效评价标准中的术语）或部分缓解率（PR，实体瘤疗效评价标准中的术语）、减少不良反应、提高生活质量（QoL）、调节免疫、减轻疼痛、延长生存期、减少转移和复发、减轻炎症、调节雌激素水平、降低高凝状态以及降低肿瘤标志物等方面。
结论
代表化瘀疗法的该方剂在癌症治疗中具有良好的前景。
Zotero 插件